Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Individuals living with HIV, particularly those on highly active antiretroviral therapy (HAART), face an increased risk of cardiovascular disease.
• Managing atherosclerotic cardiovascular disease (ASCVD) risk is crucial in the aging HIV population.
• Low-to-moderate ASCVD risk stratification is essential for targeted interventions.

Purpose of the Study:

• To evaluate the efficacy of pitavastatin in reducing major adverse cardiovascular events (MACE) in adults living with HIV.
• To assess the impact of pitavastatin initiation on cardiovascular outcomes in patients on HAART.
• To determine the benefit of statin therapy in a specific HIV-positive demographic with defined cardiovascular risk.

Main Methods:

• A study involving adults aged 40 to 75 living with HIV and on HAART.
• Participants were stratified by low-to-moderate 10-year ASCVD risk.
• Intervention group received pitavastatin; a control group likely received a placebo or standard care (details not provided in abstract).

Main Results:

• Initiation of pitavastatin significantly decreased the incidence of MACE.
• The benefit was observed in the target population of HIV-positive adults aged 40-75 with low-to-moderate ASCVD risk.
• Specific MACE reduction data not detailed in the abstract.

Conclusions:

• Pitavastatin is an effective intervention for reducing MACE in adults living with HIV on HAART with low-to-moderate ASCVD risk.
• Statin therapy, specifically pitavastatin, should be considered for cardiovascular risk management in this patient group.
• Early initiation of pitavastatin may mitigate cardiovascular events in HIV-positive individuals.